



<p>1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>					ATTY DOCKET NO. TSRI 419.0 C1	SERIAL NO. 09/081,522	
					APPLICANT Brooks, et al.	FILING DATE 05/19/98	GROUP 1644
U.S. PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
							
FOREIGN PATENT DOCUMENTS							
EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)							
<i>AC</i>	1	Christofanilli, et al., "Angiogenesis Modulation In Cancer Research: Novel Clinical Approaches", <u>Nature Reviews</u> 1: 415-426 (2002)					
							
EXAMINER <i>Pittman GmB2</i>				DATE CONSIDERED <i>4/1/04</i>			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

09/08/522

05/19/98

GROUP  
1644

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
M	A01	5,766,591	6/16/98	Brooks et al.			
	A02						
	A03						
	A04						
FEI 23 2004	A05						
	A06						
	A07						
	A08						
	A09						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	YES	NO
	B01								
	B02								
	B03								
	B04								
	B05								

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

M	C01	Gutheil, et al., "Targeted Antiangiogenic Therapy for Cancer Using vitaxin: A Humanized Monoclonal Antibody to the Integrin $\alpha_v\beta_3$ ", Clin.Cancer Research 6: 3056-3061 (2000).
	C02	
	C03	

EXAMINER

Pitmeier/Gruber 4/2/04

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Use several sheets if necessary)

09/08/52

Brooks et al.

FILING DATE  
05/19/98

GROUP  
1644

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PL	A01	5,578,704	11/26/96	Kim			
	A02	5,652,109	7/29/97	Kim			
	A03	5,652,110	7/29/97	Kim			
	A04	5,677,181	10/14/97	Parish			
	A05	5,874,081	02/23/99	Parish			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	B01	WO 94/10331	5/11/94				YES NO

**OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)**

	C01	Adams et al., "Increased Affinity Leads to Improved Selective Tumor Delivery of Single-Chain Fv Antibodies," <i>Cancer Research</i> 58: 485-490 (1998).
	C02	Carmeliet, "Integrin indecision," <i>Nature Medicine</i> 8: 14-16 (2002).
	C03	Cheresh, "Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor," <i>Proc. Natl. Acad. Sci USA</i> 84: 6471-6475 (1987).
	C04	Cheresh et al., "Integrin-mediated death: An explanation of the integrin-knockout phenotype?" <i>Nature Medicine</i> 8:193-194 (2002).
	C05	Posey et al., "Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti $\alpha_5\beta_3$ ) Antibody in Patients with Metastatic Cancer," <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> 16: 125-132 (2001).
	C06	Rader et al., "Phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries," <i>Proc. Natl. Acad. Sci. USA</i> 95: 8910-8915 (1998).
	C07	Reynolds et al., "Enhanced pathological angiogenesis in mice lacking $\beta_3$ integrin or $\beta_3$ and $\beta_5$ integrins," <i>Nature Medicine</i> 8: 27-34 (2002).
	C08	Schier et al., "Isolation of High-affinity Monomeric Human Anti-c-erbB-2 Single chain Fv Using affinity-driven Selection," <i>J. Mol. Biol.</i> 255: 28-43 (1996).
PL	C09	Schier et al., "Isolation of Picomolar Affinity Anti-c-erbB-2 Single-chain Fv by Molecular Evolution of the Complementarity Determining Regions in the Center of the Antibody Binding Site," <i>J. Mol. Biol.</i> 263: 551-567 (1996).

EXAMINER

Philip Gamber

DATE CONSIDERED

4/12/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.